Fiche publication
Date publication
mai 2022
Journal
Autophagy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr LIMAGNE Emeric
Tous les auteurs :
Limagne E, Ghiringhelli F
Lien Pubmed
Résumé
Resistance to chemo-immunotherapy is a major issue for the treatment of non-small cell lung cancer. In a recent paper we unravel the role of MAPK in the capacity of restraining the therapeutic efficacy of chemo-immunotherapy. Inhibition of the MAPK pathway using a MAP2K/MEK inhibitor in combination with chemotherapy could promote OPTN (optineurin)-dependent mitophagy of cancer cells. Mitochondria then degrade via autophagosomes and amphisomes and release mitochondrial DNA, which interacts with TLR9 located in these compartments. TLR9 activation promotes the production of the chemokine CXCL10 by cancer cells, which could further improve T cell recruitment and improve the efficacy of immunotherapy.
Mots clés
CXCL10, Chemotherapy, MAP2K/MEK inhibitor, TLR9, ULK1, immunotherapy, mitophagy, optineurin
Référence
Autophagy. 2022 May 9;:1-2
